MPM ASSET MANAGEMENT LLC
Q4 2023 Form 13-F
BOSTON, MASSACHUSETTS
CIK 0001263048
· CRD 148467
· SEC-registered investment adviser
$203.5M Reported Value Total
MPM BIOIMPACT reports 28 total accounts under management (AUM). There are 28 discretionary accounts valued at $3,360,521,440, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
34 funds
· $3.5B gross asset value
Other: $1.7B · Venture Capital Fund: $1.3B · Hedge Fund: $526.0M
Source: Form ADV filed 2026-04-28
Reported value
$203.5M
Quarter over quarter
+8.1%
Holdings
7
Top-10 concentration
100.0%
Key People
Form ADV owners & control persons
Ansbert Karl Gadicke
MANAGING MEMBER
Todd Thomas Foley
MANAGING DIRECTOR
Brendan Michael Furey
CHIEF COMPLIANCE OFFICER
Filing Navigation
Coverage begins with the second quarter of 2013. Earlier quarters are not shown while their accuracy is being verified.
13F Metrics
Loading 13F Metrics
Q4 2023 13F record
Q4 2023 13F filing summary
| Period of report | December 31, 2023 |
|---|---|
| Filed | February 13, 2024 |
| Form | 13F-HR |
| Reported value | $203.5M |
| Positions | 7 |
| Change in reported value | +9.0% |
| New positions | 1 |
| Exited positions | 1 |
| Position turnover | 25.0% |
| Top-10 concentration | 100.0% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2025 13F
Filed Nov 14, 2025
|
4 | $44.5M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
5 | $43.3M |
|
Q1 2025 13F
Filed May 15, 2025
|
6 | $69.4M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
6 | $124.4M |
|
Q3 2024 13F
Filed Nov 13, 2024
|
6 | $145.3M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
6 | $182.1M |
|
Q1 2024 13F
Filed May 15, 2024
|
6 | $245.2M |
|
Q4 2023 13F
Filed Feb 13, 2024
|
7 | $203.5M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
7 | $186.7M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
8 | $203.9M |
|
Q1 2023 13F
Filed May 12, 2023
|
9 | $240.0M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
9 | $239.0M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
9 | $262.6M |
|
Q2 2022 13F
Filed Aug 11, 2022
|
10 | $237.0M |
|
Q1 2022 13F
Filed May 13, 2022
|
10 | $292.6M |
|
Q4 2021 13F
Filed Feb 11, 2022
|
10 | $462.7M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
9 | $431.5M |
|
Q2 2021 13F
Filed Aug 13, 2021
|
9 | $537.9M |
|
Q1 2021 13F
Filed May 13, 2021
|
8 | $517.6M |
|
Q4 2020 13F
Filed Feb 16, 2021
|
8 | $706.6M |
30 earlier quarters on file — choose one from the quarter menu above.
Top 7 holdings · Q4 2023
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | TRDA Entrada Therapeutics, Inc. | $66.8M | 32.82% |
| 2 | DYN Dyne Therapeutics, Inc. | $65.9M | 32.36% |
| 3 | ITOS iTeos Therapeutics, Inc. | $30.0M | 14.74% |
| 4 | HOWL Werewolf Therapeutics, Inc. | $16.5M | 8.13% |
| 5 | RPTX Repare Therapeutics, Inc. | $16.4M | 8.04% |
| 6 | ADAPY Adaptimmune Therapeutics plc | $4.4M | 2.16% |
| 7 | HARP Harpoon Therapeutics, Inc. | $3.6M | 1.75% |
Values as reported on the Q4 2023 Form 13F. Every position is in the holdings table below.